A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT04045028 · TERMINATED

Trial details

NCT number: NCT04045028
Sponsor: Genentech, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma Non-Hodgkin Lymphoma B-Cell Lymphoma

Start date: 2019-07-22
Primary completion: 2023-03-28
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.